Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Adlai Nortye Group Ltd

ANL ✓ COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$15.09

▲ +2.69%

Market Cap $971.76M · Vol 50.39K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$971.76M

Small Cap

Div Yield

N/A

EPS Growth

+54.05%

YoY

RSI (14)

59.16

Momentum

Beta

N/A

vs Market

52W High

$17.20

12.27% below

52W Low

$0.90

1,576.67% above

Volume

50.39K

Avg 39.86K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

95.89%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Adlai Nortye Group Ltd (ANL) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ANL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+8.91%

+14.06%

+44.13%

+69.55%

YTD

+962.68%

+762.29%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$5.00M
Net Income	$-35,528,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-713.96%
Net Profit Margin	-710.56%
ROE	N/A
ROA · ROIC	-67.22% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	9.08
P/B	N/A
P/FCF	N/A
EPS Growth	+54.05%
Outstanding Shares	193.19M

Technical Indicators

50-Day SMA	$12.80
200-Day SMA	$9.20
RSI (14)	59.16
Beta	N/A
52-Week High	$17.20
52-Week Low	$0.90

Volume Today	50.39K
Avg Daily Volume (30D)	39.86K
Relative Volume	1.26x
Volatility (10D)	61.85
Volatility (30D)	58.55
Free Float	95.89%

Analyst Consensus

BUY

Current Price $15.09

Mean Target $29.50

52W Low$0.90 52W High$17.20

Current

Target

$0.90 $17.20

Current Analyst target

+95.49% upside potential · 6 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG01HP11TP9

ISINUS00704R1095

CountrySingapore

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -0.56% ONC BeOne Medicines AG -2.62% 068270.KS Celltrion, Inc. -1.26% ABVX Abivax SA -2.94% ABVX.PA Abivax SA -0.89%

Company Profile

Adlai Nortye Group Ltd. is a clinical-stage biotechnology company. The Company is engaged in the research and development of pharmaceutical products. It is developing targeted and immune-modulating cancer therapies. Its RAS-targeting portfolio includes AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate (ADC) delivering a potent pan-RAS(ON) inhibitor directly to tumors. It is also developing cancer immunotherapies, including AN8025, a tri-functional fusion protein (aPD-L1 × CD86 variant × LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which are designed to activate cancer immunity in novel ways. Its pipeline also includes AN0025, a small molecule EP4 antagonist designed to modulate the tumor microenvironment.